文献速递炎症性肠病

间充质干细胞治疗肛瘘型克罗恩病的有效性与安全性评价:一项国际真实世界回顾性多中心队列研究

Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study.
PubMed 文献 · Aliment Pharmacol Ther · 2024-10-28

该国际多中心回顾性队列纳入223例克罗恩病肛瘘患者,评估darvadstrocel治疗的有效性与安全性。第26周和第52周肛周临床缓解率分别为78.2%和62.3%,临床应答率分别为84.8%和79.8%。13.5%的患者发生不良事件,以肛周脓肿和直肠痛最常见。

要点

  • 第26周和第52周肛周临床缓解率分别为78.2%和62.3%,临床应答率分别为84.8%和79.8%。
  • 基线PDAI评分(OR 0.75)、瘘管数量(OR 0.28)和手术准备后周数(OR 0.98)与治疗失败相关。
  • 13.5%的患者发生不良事件,肛周脓肿和直肠痛最常见;患者满意度高。

核心结论

  • 疗效数据高于临床试验,安全性令人放心,患者满意度高,适当的患者选择、瘘管准备和专业技术可能有助于治疗成功。

研究设计与样本

  • 国际真实世界回顾性多中心队列研究,纳入223例克罗恩病合并肛周瘘管患者,评估darvadstrocel治疗。

主要发现

  • 截至第26周和第52周,肛周临床缓解率分别为78.2%和62.3%。
  • 第26周和第52周临床应答率分别为84.8%和79.8%。
  • 主观肛周症状改善率分别为77.8%和78.4%。
  • 基线PDAI评分(OR 0.75)、瘘管数量(OR 0.28)和手术准备后周数(OR 0.98)与治疗失败相关。
  • 13.5%的患者发生不良事件,肛周脓肿和直肠痛最常报告。

关键数值与推荐

  • 肛周临床缓解定义为所有治疗瘘管闭合。
  • 临床应答定义为至少1个瘘管闭合。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety of adipose-derived mesenchymal stem cell treatment are contradicting, and real-world evidence is lacking. AIMS: To examine the usability of darvadstrocel therapy in managing perianal CD. METHODS: We enrolled patients with CD and perianal fistulas in this retrospective multicenter study. The primary outcome was perianal clinical remission (defined as all treated fistulas closed) at weeks 26 and 52. Secondary outcomes were clinical response rates (≥ 1 fistulas closed), perianal activity (PDAI), patient satisfaction, and adverse events. Data were recorded at baseline and weeks 12, 26 and 52. Prediction of primary outcomes was performed by logistic regression. RESULTS: Overall, among 223 patients (male/female ratio: 0.48), perianal clinical remission was achieved in 78.2% and 62.3% until weeks 26 and 52. Baseline PDAI score (OR 0.75), number of fistulas (OR 0.28) and the number of weeks after preparation for surgery (OR 0.98) were associated with treatment failure. The clinical response rates were 84.8% and 79.8% at weeks 26 and 52. Improvement of subjective perianal symptoms was achieved in 77.8% and 78.4% of patients, respectively. Adverse events occurred in 13.5% of patients; perianal abscesses and proctalgia were the most frequently reported. CONCLUSION: Effectiveness data were higher than in clinical trials. The safety profile was reassuring, and patients' satisfaction was high. Appropriate patient selection, fistula preparation and expertise may help to achieve treatment success.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bacsur P, Shaham D, Serclova Z, et al. Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study. Aliment Pharmacol Ther. 2024. PMID: 39468719. doi:10.1111/apt.18359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。